S

    Stryker Corporation (SYK)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $330.69
    +8.57 (+2.66%)

    Market Cap: $126.84B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    85%(34/40)
    Avg Surprise
    +3.52%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$3.59
    Range$3.44 - $3.80
    24 analysts
    EPS Revisions
    1
    0
    7d
    1
    19
    30d
    EPS Estimate Drift
    90d ago$3.69+2.7%
    60d ago$3.68+2.6%
    30d ago$3.68+2.6%
    7d ago$3.60+0.2%
    Current$3.59
    Revenue Consensus
    $6.7B
    Range$6.6B - $6.8B
    25 analysts
    Dec 31, 2026
    EPS Consensus$4.95
    Range$4.84 - $5.01
    27 analysts
    Revenue Consensus
    $7.7B
    Range$7.5B - $7.9B
    27 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$4.95---
    Sep 26EST
    		-$3.59---
    Jun 26
    		$3.69$3.46+6.65%Beat+17.9%
    Mar 26
    		$2.60$2.98-12.75%Miss-8.5%
    Dec 25
    		$4.47$4.40+1.59%Beat+11.5%
    Sep 25
    		$3.19$3.13+1.92%Beat+11.1%
    Jun 25
    		$3.13$3.07+1.95%Beat+11.4%
    Mar 25
    		$2.84$2.73+4.03%Beat+13.6%
    Dec 24
    		$4.01$3.87+3.62%Beat+15.9%
    Sep 24
    		$2.87$2.77+3.61%Beat+16.7%
    Jun 24
    		$2.81$2.79+0.72%Beat+10.6%
    Mar 24
    		$2.50$2.36+5.93%Beat+16.8%
    Dec 23
    		$3.46$3.27+5.81%Beat+15.3%
    Sep 23
    		$2.46$2.44+0.82%Beat+16.0%
    Jun 23
    		$2.54$2.38+6.72%Beat+12.9%
    Mar 23
    		$2.14$2.00+7.00%Beat+8.6%
    Dec 22
    		$3.00$2.84+5.63%Beat+10.7%
    Sep 22
    		$2.12$2.23-4.93%Miss-3.6%
    Jun 22
    		$2.25$2.28-1.32%Miss+0.0%
    Mar 22
    		$1.97$1.92+2.60%Beat+2.1%
    Dec 21
    		$2.71$2.72-0.37%Miss-3.6%
    Sep 21
    		$2.20$2.28-3.51%Miss+2.8%
    Jun 21
    		$2.25$2.13+5.63%Beat+251.6%
    Mar 21
    		$1.93$1.98-2.53%Miss+4.9%
    Dec 20
    		$2.81$2.55+10.20%Beat+12.9%
    Sep 20
    		$2.14$1.43+49.65%Beat+12.0%
    Jun 20
    		$0.64$0.57+12.28%Beat-67.7%
    Mar 20
    		$1.84$1.74+5.75%Beat-2.1%
    Dec 19
    		$2.49$2.46+1.22%Beat+14.2%
    Sep 19
    		$1.91$1.90+0.53%Beat+13.0%
    Jun 19
    		$1.98$1.94+2.06%Beat+12.5%
    Mar 19
    		$1.88$1.84+2.17%Beat+11.9%
    Dec 18
    		$2.18$2.15+1.40%Beat+11.2%
    Sep 18
    		$1.69$1.68+0.60%Beat+11.2%
    Jun 18
    		$1.76$1.73+1.73%Beat+15.0%
    Mar 18
    		$1.68$1.60+5.00%Beat+13.5%
    Dec 17
    		$1.96$1.95+0.51%Beat+10.1%
    Sep 17
    		$1.52$1.50+1.33%Beat+9.4%
    Jun 17
    		$1.53$1.51+1.32%Beat-
    Mar 17
    		$1.48$1.43+3.50%Beat-
    Dec 16
    		$1.78$1.76+1.14%Beat-
    Sep 16
    		$1.39$1.37+1.46%Beat-

    Dividends

    Dividend Metrics

    Yield1.05%
    Annual/Share$3.48
    Payout Ratio24.16%
    Frequency4
    Pay MonthsJan, Apr, Jul, Oct

    Growth

    3Y CAGR+6.25%
    5Y CAGR+7.62%
    View SYK's full dividend history

    Key Metrics

    Valuation
    P/E Ratio23.71EV/EBITDA19.37x
    Price/FCF26.97xFCF Yield3.71%
    Profitability
    Profit Margin14.40%Operating Margin27.00%
    ROE16.50%ROIC11.25%
    Financial Health
    Debt/Equity0.62xInterest Coverage12.23x
    Current Ratio2.16xQuick Ratio1.33x
    Trading Statistics
    Beta0.77Avg Volume2.37M
    52-Week High$392.8652-Week Low$280.25

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$330.11
    SMA 20$335.66
    SMA 50$328.54
    SMA 200$338.70
    EMA 10$330.64
    EMA 20$332.19
    EMA 50$329.05
    EMA 200$337.64

    MACD

    Line: -0.62Signal: 1.23Hist: -1.85

    ADX

    ADX: 8.4+DI: 20.3-DI: 22.1

    Aroon & PSAR

    Aroon Up12.0
    Aroon Down20.0
    PSAR$337.69

    Bollinger Bands

    Upper Band$349.93
    Lower Band$321.39
    %B Position850%(Upper)
    Band Width0.33

    RSI (14-Day)

    Neutral
    49.2

    Momentum Oscillators

    Stoch %K18.7
    Stoch %D18.7
    Williams %R-67.7
    ROC (10d)-2.5%
    Momentum-8.52
    CCI (20d)-95.0
    MFI (14d)30.0

    Volatility Measures

    ATR (14d)$9.74(2.9%)
    StdDev (20d)7.14
    Hist Vol30.8%(Moderate)

    Volume Flow

    VWAP$328.51
    OBV-25.5M
    AD Line-245.4M
    CMF (20d)0.052

    Volume Metrics

    Avg Vol (20d)2.2M
    Vol Ratio1.0x
    VWMA (20d)$335.29

    Pivot Points

    R3$333.36
    R2$330.91
    R1$326.51
    Pivot Point$324.06
    S1$319.66
    S2$317.21
    S3$312.81

    Advanced Oscillators

    TSI-1.37
    Ultimate Osc42.6
    KST4.86

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$6.59B$6.02B$7.17B$6.06B$6.02B$5.87B$6.44B$5.49B$5.42B$5.24B$5.82B$4.91B
    Cost of Revenue$2.09B$2.21B$2.54B$2.21B$2.18B$2.12B$2.26B$1.98B$2.01B$1.91B$2.11B$1.75B
    Gross Profit$4.50B$3.81B$4.63B$3.85B$3.84B$3.74B$4.17B$3.52B$3.42B$3.33B$3.70B$3.16B
    Operating Expenses$2.84B$2.87B$2.82B$2.72B$2.73B$2.91B$3.59B$2.43B$2.37B$2.36B$2.45B$2.23B
    R&D$434.00M$413.00M$401.00M$410.00M$407.00M$405.00M$358.00M$377.00M$363.00M$368.00M$350.00M$353.00M
    SG&A$2.23B$2.28B$2.23B$2.04B$2.08B$2.30B$2.12B$1.89B$1.83B$1.84B$1.91B$1.71B
    Operating Income$1.66B$936.00M$1.80B$1.14B$1.11B$837.00M$581.00M$1.08B$1.05B$972.00M$1.26B$931.00M
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$141.00M$148.00M$99.00M$106.00M$159.00M$137.00M$53.00M$42.00M$53.00M$49.00M$31.00M$62.00M
    Income Before Tax$1.56B$850.00M$1.71B$1.03B$1.02B$764.00M$528.00M$1.04B$998.00M$923.00M$1.23B$869.00M
    Income Tax Expense$288.00M$105.00M$856.00M$170.00M$132.00M$110.00M$-18,000,000$209.00M$173.00M$135.00M$83.00M$177.00M
    Net Income$1.28B$745.00M$849.00M$859.00M$884.00M$654.00M$546.00M$834.00M$825.00M$788.00M$1.14B$692.00M
    EBITDA$2.00B$1.30B$2.63B$1.34B$1.47B$1.17B$1.20B$1.31B$1.26B$1.18B$1.84B$1.13B
    EBIT$1.71B$998.00M$2.31B$1.03B$1.18B$901.00M$937.00M$1.04B$998.00M$923.00M$1.59B$869.00M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    The Aristocrat Nobody Wanted: Why (MDT) Is Worth a Second Look Right Now

    (MDT) has raised its dividend for 48 consecutive years, yet trades at just 14x forward earnings. On a trailing basis it is 24x vs. (ISRG) at 57x and (SYK) at 40x. The 5-year dividend CAGR is 4.4%, slowing to 2.0% over three years. This is a yield anchor at 3.3%, not a fast compounder. Payout ratio of 50.2% keeps the streak sustainable. FCF yield sits near 4.87% with $5.41B in trailing free cash flow. Ten straight years of positive FCF. The income is backed by real cash generation. Revenue grew 8.7% in the most recent quarter, the company's strongest enterprise growth in 10 quarters. Full-year guidance raised then reiterated. Two consecutive beats matter. Blended fair value from multiple sources lands near $107-$108 vs. current price near $86, implying roughly 24-25% upside before the 3.3% yield. GNG Research internal FV is $94.01. EPS beat rate over the last 8 quarters: 100%. The market is pricing this like a business that disappoints. The data from the GNG Research terminal shows otherwise.

    Unknown Author
    •
    4/8/26
    •
    138
    dividend aristocrats
    value investing
    Medical Devices
    Also mentions:
    ISRG
    ABT
    SYK

    Why TransMedics Stock is a Buy for Long-Term Investors

    TransMedics is replacing a 60-year-old organ-transport method with its FDA-approved OCS platform, which keeps hearts, lungs, and livers alive and functioning during transit — a massive step-change in reliability and outc Business model now prints cash: $250K consoles + $80–100K per-procedure recurring revenue + the scaling National OCS Program (NOP) aircraft fleet. Margins expanding, FCF inflection is real. Financials are inflecting sharply: EPS beat (+83%), strong operating leverage, rising gross margins, and guidance moving higher even with temporary revenue noise. Short-term volatility ≠ broken thesis: Stock recently sold off on a slight revenue miss and high short interest, but fundamental adoption trends remain strong across transplant centers. Long-term runway is substantial: Multi-organ expansion, NOP scaling, higher utilization rates, and future indications (including kidney) create years of growth. GNG Research Rating — BUY on weakness: Best accumulation zone is sub-$110, with long-term fair value well above current levels based on sustained growth, rising margins, and expanding TAM.

    Unknown Author
    •
    11/14/25
    •
    266
    medical-technology
    healthcare-innovation
    organ-transplant
    growth-stocks
    Also mentions:
    ISRG
    SYK
    MDT
    ABT
    EW

    Government Contracts

    Gov Obligations (TTM)
    $74.47M
    Gov Obligations / Revenue
    0.3%
    Obligations YoY
    9.3%
    Active Awards
    5,562
    New Awards (TTM)
    5,479
    Avg Remaining Term
    8.6 mo

    Top agency: Department of Defense at 74.8% of trailing twelve month obligations across 6 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C24426N0793Department of Veterans AffairsDepartment of Veterans Affairs$5.60MJun 30, 2026
    36C25926N0341Department of Veterans AffairsDepartment of Veterans Affairs$1.75MJun 22, 2026
    36C24526N0738Department of Veterans AffairsDepartment of Veterans Affairs$1.19MJul 16, 2026
    36C25026N0391Department of Veterans AffairsDepartment of Veterans Affairs$1.07MMar 10, 2026
    36C26126P0453Department of Veterans AffairsDepartment of Veterans Affairs$990000Feb 25, 2026
    SPE2D625F2NADDepartment of DefenseDefense Logistics Agency$920000Sep 4, 2025
    70US0926F2GSA2360Department of Homeland SecurityU.S. Secret Service$517447Jun 5, 2026
    36C24826N0538Department of Veterans AffairsDepartment of Veterans Affairs$480000May 1, 2026
    36C24426F0234Department of Veterans AffairsDepartment of Veterans Affairs$311438Jul 22, 2026
    SPE2D626F4V3GDepartment of DefenseDefense Logistics Agency$307850Apr 10, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Fundsmith LLP Has $917.39 Million Holdings in Stryker Corporation $SYK

    Fundsmith LLP significantly reduced its stake in Stryker Corporation (NYSE:SYK) by 4.8% in the second quarter, now holding 2,913,833 shares valued at over $917 million, making it their second-largest holding. Despite this reduction, other institutional investors have recently acquired new positions in Stryker. The medical technology company reported strong Q2 earnings, beating analyst estimates, and has declared a quarterly dividend of $0.88 per share.

    MarketBeat•8/31/26•
    Neutral

    Alyeska Investment Group L.P. Makes New $52.74 Million Investment in Stryker Corporation $SYK

    Alyeska Investment Group L.P. has acquired a new stake worth $52.74 million in Stryker Corporation (NYSE:SYK) during the second quarter. Other institutional investors have also increased their holdings in the medical technology company. Analysts have issued various ratings and price targets for Stryker, with the company currently holding a "Moderate Buy" rating and an average price target of $386.28.

    MarketBeat•8/31/26•
    Somewhat-Bullish

    Stryker and IAGE partner to advance clinical excellence in fluorescence-guided surgery in gynaecology in India

    Stryker, a global medical technologies leader, has partnered with the Indian Association of Gynaecological Endoscopists (IAGE) to enhance surgeon education in fluorescence-guided surgery (FGS) for gynaecology in India. This collaboration aims to provide high-quality educational opportunities and facilitate knowledge exchange among surgeons, ultimately improving patient care in minimally invasive gynaecological procedures. The partnership will deliver pan-India clinical educational initiatives over the next two years.

    PR Newswire•8/31/26•
    Bullish

    Stryker Corporation $SYK Shares Sold by Benjamin Edwards Inc.

    Benjamin Edwards Inc. reduced its stake in Stryker Corporation ($SYK) by 11.6% in the second quarter, selling 18,177 shares and holding 138,678 shares valued at $43.68 million. Other institutional investors also adjusted their holdings, with minor increases reported by several firms. Additionally, two insiders, Ronda E. Stryker and Dylan Bram Crotty, sold a significant number of shares totaling over $100 million in separate transactions.

    MarketBeat•8/30/26•
    Neutral

    Royal London Asset Management Ltd. Reduces Position in Stryker Corporation $SYK

    Royal London Asset Management Ltd. slightly reduced its stake in Stryker Corporation (NYSE:SYK) by 1.1% in the second quarter, selling 3,684 shares, though it still holds 340,466 shares valued at $107.2 million. Despite this reduction, many other institutional investors increased their positions, with institutions collectively owning 77.09% of the company. Stryker reported strong quarterly earnings of $3.69 per share, beating estimates, and revenue grew 9.4% to $6.59 billion, while also maintaining its fiscal 2026 EPS guidance.

    MarketBeat•8/29/26•
    Somewhat-Bullish

    Frequently Asked Questions About SYK

    What is SYK's current dividend yield?
    Stryker Corporation (SYK) has a current dividend yield of 1.05%.
    Does SYK pay dividends?
    Yes, Stryker Corporation pays dividends with a current yield of 1.05%.
    What is SYK's P/E ratio?
    Stryker Corporation has a price-to-earnings (P/E) ratio of 23.71.
    What is SYK's market cap?
    Stryker Corporation (SYK) has a market capitalization of $126.84B with a current stock price of $330.69.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In